Adimans Technologies LLP files SEBI takeover disclosure under Regulation 31(4) for Dishman Carbogen Amcis Limited
Adimans Technologies LLP submitted a Regulation 31(4) disclosure to NSE for Dishman Carbogen Amcis Limited, a pharmaceutical company. Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 requires disclosure when a party acquires or disposes of shares such that their shareholding crosses specified thresholds (typically 5%, 10%, 15%, 20%, 25%, 30%, etc.). The filing was processed on or around 30 June 2026. Substantive transaction terms, consideration, and strategic intent remain unknown from publicly available sources.
Why it mattersA Regulation 31(4) disclosure signals a party has crossed a material shareholding threshold; without sight of the full Form 31 or company announcement, the specific gating event (5%, 10%, 25% threshold) and deal mechanics remain unconfirmed.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Corporate Archives · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026